The study of prethrombotic state in patients with lung cancer

Chinese Journal of Lung Cancer

Volumn 12, Issue 1, 2009, Pages 44-48

  Jiang, Zhenghua ^a   Sang, Huiying ^a   Ge, Hui ^a   Zhu, Muyun ^a   Sang, Linlii ^a   Wang, Zhengdong ^a  

^a NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

Author keywords

Lung neoplasms; Prethrombotic state; Prognosis

Indexed keywords

ANTITHROMBIN III; D DIMER; FIBRINOGEN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BLOOD CLOTTING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENDER; HISTOLOGY; HUMAN; HYPERCOAGULABILITY; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIMARY TUMOR; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; THROMBOSIS; THROMBUS; TUMOR VOLUME;

EID: 60149088796     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2009.01.007     Document Type: Article

References (22)

1. Kalweit GA, Feindt P, Micek M, et al. Markers of activated hemostasis and fibrinolysis in patients with pulmonary malignancies: comparison of plasma levels in central venous and pulmonary venous blood. Thromb Res, 2002, 97(3): 105-111.
2. Lu WX, Li LY, Gao Y, et al. Thrombosis diseases and lung cancer. Chin J Tubere Respir Dis, 2000, 23(7): 400-402.
3. Zhang JX, Cui CB. The clinical analysis of 18 patients with lung cancer complicated with venous thromboembolism. Chin J Lung Cancer, 2006, 9(6): 550-551.
4. Huang Y, Cheng JK, Jing X, et al. Changes and clinical vaule of coagulation function in patients with lung cancer. Chin J Clin Lab Sci, 2005, 23(4): 296-297.
5. Li Y, Hang LX. The clinical value oi coagulation markers in patients with malignant tumor. Mod J Integ Trad Chin West Med, 2006, 15(5): 636-637.
6. Sallah S, Wan JY, Nguyen NP. Venous thrombosis in patients with solid tu-mors: Determination of frequency and characteristics. Thromb Haemost, 2002, 7: 576-579.
7. Cheng SX, Wu LB, Jiang YY. The study of coagulation state in patients with lung cancer. Chin J Cancer Prev Treat, 2004, 11(1): 111-112.
8. Wang MS, Yang LH, Pan JY, et al. Dynamic changes and signif icance of antithrombin and fibrinolytic function in advanced lung cancer patients during chemotherapy. Chin J Lung Cancer, 2007, 10(3): 226-228.
9. Yeh PS, Lin HJ. Cerebrovascular complications in patients with malignancy: report of three cases and review of the literature. Acta Neurol Taiwan, 2004, 13(1): 34-38.
10. Yamaguchi T, Yamamoto Y, Yokota S, et al. Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol, 1998, 28(12): 740-744.
11. Yamaguchi T, Yamamoto Y, Yokota S, et al. Effect of IL-6 elevation in malignant pleural effusion on hyperfibrinogenemia in lung cancer patients. Jpn J Clin Oncol, 2000, 30(2): 53-58.
12. Yan F, Zhang DC, Li AW, et al. Clinical value of hemorrheological changes in lung cancer patients of different stages. Mod Oncol, 2004, 12(1): 277-278.
13. Bai QY, Zhang JX. Analysis on the changes of coagulation function in patients with lung cancer. Zhejiang J Integ Trad Chin West Med, 2006, 16(11): 683-684.
14. Liu CQ. Study on the changes of coagulation state in patients with lung cancer. Hebei Med J, 2007, 29(9): 929-930.
15. Jones JM, McGonigle NC, McAnespie M, et al. Plasma fibrinogen and seium C-reactive protein are associated with non-small cell lung cancer. Lung Cancer, 2006, 53(1): 97-101.
16. Wu JH, Shi WJ, Ju WD, et al. The correlative study of coagulation function in patients with lung cancer. J Clin Exper Med, 2006, 5(8): 1140-1141.
17. Wang CC, Cao MG. Variation of coagulation and fibrinolytic molecular markers in lung cancer patients. Med Lab Sci Clin, 2007, 18(2): 41-42.
18. Unsal E, Atalay F, Atikan S, et al. Prognostic significance of hemostatic parameters in patients with lung cancer. Respir Med, 2004, 98(2): 93-98.
19. Buccheri G, Ferrigno D, Ginardi C, et al. Haemostatic abnormalities in lung cancer: prognostic implications. Eur J Cancer, 1997, 33(1): 50-55.
20. Pavey SJ, Hawson GA, Marsh NA. Impactof the fibrinolytic enzyme system on prognosis and survival associated with non-small cell lung carcinoma. Blood Coagul Fibrinol, 2001, 12(1): 51-58.
21. Antoniou D, Pavlakou G, Stathopoulos GP, et al. Predictive value of D-dimer plasma levels in response and progressive disease in patients with lung cancer. Lung Cancer, 2006, 10(4): 1222-1227.
22. Buccheri G, Torchio P, Ferrigno D. Plasma levels of D-dimer in lung carcinoma: clinical and prognostic significance. Cancer, 2003, 97(12): 3044-3052.